The discovery of heterozygous germline mutations in BMPR2, the gene encoding bone morphogenetic protein receptor type 2, in patients with familial and idiopathic forms of pulmonary arterial hypertension (PAH) was another breakthrough in understanding the disease and initiated a new era in care of patients with this condition2. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.